Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease

By Michael Bartl, MD, Mohammed Dakna, Douglas Galasko, Samantha J. Hutten, Tatiana Foroud, Marian Quan, Ken Marek, MD, Andrew Siderowf, Jonas Franz, MD, Claudia Trenkwalder, Brit Mollenhauer, MD

Published October 7, 2021

View Published Article

Description

Several pathophysiological processes are involved in Parkinson’s disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer’s Disease, in a PD cohort. Except for αSyn, the additional biomarkers did not differentiate PD and HC, and none showed longitudinal differences, but most markers predict cognitive decline in PD during follow-up.

Identifier (DOI)

10.1371/journal.pone.0257372

Tags

Biomarkers
CSF (Cerebral Spinal Fluid)
Original Research
Parkinson's disease

Program

Parkinson's Progression Markers Initiative

Meet the Authors

Michael Bartl, MD

Key Personnel: Team Schlossmacher,

Universitätsmedizin Göttingen
Mohammed Dakna

External Collaborator
Douglas Galasko

External Collaborator
Samantha J. Hutten

External Collaborator
Tatiana Foroud

External Collaborator
Marian Quan

External Collaborator
Ken Marek, MD

University of California, San Diego
Andrew Siderowf

External Collaborator
Jonas Franz, MD

Key Personnel: Team Schlossmacher,

Universitätsmedizin Göttingen
Claudia Trenkwalder

External Collaborator
Brit Mollenhauer, MD

Co-PI (Core Leadership): Team Schlossmacher,

University of Goettingen